SLXN Silexion Therapeutics Corp.
Silexion Therapeutics Corp. (SLXN) is expected to report earnings on November 13, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of +1.4% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Silexion Therapeutics Corp.
Silexion Therapeutics Ltd. is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. Silexion Therapeutics Ltd., formerly known as Biomotion Sciences, is based in NEW YORK.
Sector
Healthcare
Industry
Biotechnology